Skip to main content

A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer.

Publication ,  Journal Article
Anders, C; Marcom, PK; Peterson, B; Gu, L; Unruhe, S; Welch, R; Lyons, P; Behera, M; Copland, S; Kimmick, G; Shaw, H; Snyder, S; Antenos, M ...
Published in: Cancer Invest
2008

BACKGROUND: Premenopausal women treated for early stage breast cancer (ESBC) are at risk for chemotherapy-related amenorrhea (CRA). Prospectively-validated, predictive markers of CRA are needed. PATIENTS AND METHODS: Premenopausal women with ESBC and planned chemotherapy (>/= 25% risk of amenorrhea) were evaluated. Follicle stimulating hormone (FSH), estradiol, Inhibin A and B, anti-Müllerian hormone (AMH), and quality of life (QOL) were prospectively evaluated pre-, post-, 6 months and 1 year post-chemotherapy and correlated with age and menstrual status. CRA was defined as absence of menses 1 year post-chemotherapy. RESULTS: Forty-four women were evaluated at the time of analysis. Median age at diagnosis and FSH 1 year post-chemotherapy were higher among women with CRA (44 yrs [33-51] vs. 40 yrs [31-43]; p = 0.03; 39.8 vs. 5.0 mLU/mL, p = 0.0058, respectively). Median estradiol 1 year post-chemotherapy was higher among women who resumed menses (108.3 vs. 41.3 pg/mL, p = 0.01). Pre-chemotherapy median Inhibin B and AMH were lower among women with CRA (33.2 vs. 108.8 pg/mL; p = 0.03; 0.16 vs. 1.09 ng/mL, p = 0.02, respectively). The risk of CRA was increased among women with lower pre-chemotherapy Inhibin B (RR = 1.67, p = 0.15) and AMH (RR = 1.83, p = 0.05). Amongst women whose pre-chemotherapy Inhibin B and AMH values were below the median, the incidence of CRA was 87.5%. CONCLUSIONS: RESULTS indicate that pre-chemotherapy Inhibin B and AMH are lower among women experiencing CRA and may be predictive of CRA among premenopausal women facing chemotherapy for ESBC.

Duke Scholars

Published In

Cancer Invest

DOI

EISSN

1532-4192

Publication Date

2008

Volume

26

Issue

3

Start / End Page

286 / 295

Location

England

Related Subject Headings

  • Quality of Life
  • Premenopause
  • Pilot Projects
  • Oncology & Carcinogenesis
  • Middle Aged
  • Inhibins
  • Immunoassay
  • Humans
  • Follicle Stimulating Hormone
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Anders, C., Marcom, P. K., Peterson, B., Gu, L., Unruhe, S., Welch, R., … Blackwell, K. (2008). A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest, 26(3), 286–295. https://doi.org/10.1080/07357900701829777
Anders, Carey, P Kelly Marcom, Bercedis Peterson, Lin Gu, Sue Unruhe, Renee Welch, Peggy Lyons, et al. “A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer.Cancer Invest 26, no. 3 (2008): 286–95. https://doi.org/10.1080/07357900701829777.
Anders C, Marcom PK, Peterson B, Gu L, Unruhe S, Welch R, et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest. 2008;26(3):286–95.
Anders, Carey, et al. “A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer.Cancer Invest, vol. 26, no. 3, 2008, pp. 286–95. Pubmed, doi:10.1080/07357900701829777.
Anders C, Marcom PK, Peterson B, Gu L, Unruhe S, Welch R, Lyons P, Behera M, Copland S, Kimmick G, Shaw H, Snyder S, Antenos M, Woodruff T, Blackwell K. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest. 2008;26(3):286–295.

Published In

Cancer Invest

DOI

EISSN

1532-4192

Publication Date

2008

Volume

26

Issue

3

Start / End Page

286 / 295

Location

England

Related Subject Headings

  • Quality of Life
  • Premenopause
  • Pilot Projects
  • Oncology & Carcinogenesis
  • Middle Aged
  • Inhibins
  • Immunoassay
  • Humans
  • Follicle Stimulating Hormone
  • Female